Last reviewed · How we verify
Cozaar®
Cozaar blocks angiotensin II receptors on blood vessels and tissues, causing vasodilation and reducing blood pressure.
Cozaar blocks angiotensin II receptors on blood vessels and tissues, causing vasodilation and reducing blood pressure. Used for Hypertension, Diabetic nephropathy in patients with type 2 diabetes, Heart failure with reduced ejection fraction.
At a glance
| Generic name | Cozaar® |
|---|---|
| Also known as | Losartan (generic name), Losartan |
| Sponsor | Teva Pharmaceuticals USA |
| Drug class | Angiotensin II receptor blocker (ARB) |
| Target | AT1 receptor (angiotensin II type 1 receptor) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Cozaar (losartan) is an angiotensin II receptor antagonist (ARB) that selectively blocks the AT1 receptor subtype. By preventing angiotensin II from binding to these receptors, it prevents vasoconstriction and aldosterone secretion, leading to reduced blood pressure and decreased sodium retention. This mechanism also provides renal protection in diabetic patients.
Approved indications
- Hypertension
- Diabetic nephropathy in patients with type 2 diabetes
- Heart failure with reduced ejection fraction
- Stroke risk reduction in hypertensive patients with left ventricular hypertrophy
Common side effects
- Dizziness
- Fatigue
- Hyperkalemia
- Cough
- Hypotension
- Headache
Key clinical trials
- Losartan Potassium/Hydrochlorothiazide 100/25 mg Tablets in Healthy Subjects Under Non-Fasting Conditions (PHASE1)
- Losartan 100 mg Tablet in Healthy Subjects Under Non-Fasting Conditions (PHASE1)
- An Extension Study Designed to Assess Effects of Losartan on Proteinuria in Pediatric Populations (MK-0954-326 AM1,EXT1(AM2)) (PHASE3)
- LAAS (Losartan Anti-Atherosclerosis Study)(0954-330)(COMPLETED) (PHASE4)
- A Long-term Study of the Safety of MK-0954A in Patients With Essential Hypertension (MK-0954A-351) (PHASE3)
- A Prospective, Randomised, Double-blind, Double-dummy, Forced-titration, Multicentre, Parallel Group, One Year Treatment Trial to Compare Telmisartan (MICARDIS) 80 mg Versus Losartan (COZAAR) 100 mg, in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy (AMADEO Study) (PHASE4)
- The Effect of Combined Use of Anti-fibrotic Agent With Platelet Rich Plasma on Skeletal Muscle Healing After Acute Injuries (PHASE4)
- Comparison of Losartan Associated With Indapamide Versus Hyzaar® in the Hypertension Treatment (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cozaar® CI brief — competitive landscape report
- Cozaar® updates RSS · CI watch RSS
- Teva Pharmaceuticals USA portfolio CI